KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY

Clinical trials for KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY explained in plain language.

Never miss a new study

Get alerted when new KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY trials appear

Sign up with your email to follow new studies for KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for kids with rare epilepsy: first human trial launches

Disease control Recruiting now

This study tests a new medicine, S230815, in children aged 2 to 12 with a rare genetic epilepsy called KCNT1-related developmental and epileptic encephalopathy. The goal is to see if the drug is safe and can help control seizures. The trial involves giving the drug via a spinal i…

Matched conditions: KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Jun 16, 2026 12:49 UTC

KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY

Get alerted when new KCNT1-RELATED DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY trials appear

New hope for kids with rare epilepsy: first human trial launches